This document is a Call to Action to partners in prevention from various sectors across the nation to address skin cancer as a major public health problem. Many partners are essential to this effort, including federal, state, tribal, local, and territorial governments; members of the business, health care, and education sectors; community, nonprofit, and faith-based organizations; and individuals and families. The goal of this document is to increase awareness of skin cancer and to call for actions to reduce its risk.The first section describes the problem of skin cancer and its major risk factors. It also discusses the relationship between exposure to ultraviolet (UV) radiation and health. The second section describes the current evidence on preventing skin cancer, including current initiatives in the United States and in other countries. The third section describes the gaps in research related to skin cancer prevention, highlighting areas of research where more work is needed. The fourth section identifies specific opportunities to prevent skin cancer by reducing UV exposure in the U.S. population and calls for nationwide action.

Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas.

In the late 1980s, the National Cancer Institute initiated an investigation of cancer risks in populations near 52 commercial nuclear power plants and 10 Department of Energy nuclear facilities (including research and nuclear weapons production facilities and one reprocessing plant) in the United States. The results of the NCI investigation were used a primary resource for communicating with the public about the cancer risks near the nuclear facilities. However, this study is now over 20 years old. The U.S. Nuclear Regulatory Commission requested that the National Academy of Sciences provide an updated assessment of cancer risks in populations near USNRC-licensed nuclear facilities that utilize or process uranium for the production of electricity. Analysis of Cancer Risks in Populations near Nuclear Facilities: Phase 1 focuses on identifying scientifically sound approaches for carrying out an assessment of cancer risks associated with living near a nuclear facility, judgments about the strengths and weaknesses of various statistical power, ability to assess potential confounding factors, possible biases, and required effort. The results from this Phase 1 study will be used to inform the design of cancer risk assessment, which will be carried out in Phase 2. This report is beneficial for the general public, communities near nuclear facilities, stakeholders, healthcare providers, policy makers, state and local officials, community leaders, and the media.

This User’s Guide is intended to support the design, implementation, analysis, interpretation, and quality evaluation of registries created to increase understanding of patient outcomes. For the purposes of this guide, a patient registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes. A registry database is a file (or files) derived from the registry. Although registries can serve many purposes, this guide focuses on registries created for one or more of the following purposes: to describe the natural history of disease, to determine clinical effectiveness or cost-effectiveness of health care products and services, to measure or monitor safety and harm, and/or to measure quality of care. Registries are classified according to how their populations are defined. For example, product registries include patients who have been exposed to biopharmaceutical products or medical devices. Health services registries consist of patients who have had a common procedure, clinical encounter, or hospitalization. Disease or condition registries are defined by patients having the same diagnosis, such as cystic fibrosis or heart failure. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews.

Management of Cancer in the Older Patient, by Drs. Arash Naeim, David Reuben, and Patricia Ganz, offers the help you need to effectively diagnose, refer, and manage cancer in geriatric patients. You’ll see how to provide effective cancer screening; refer your patients to the right oncologist; deal with comorbidities, frailties, and other complications; navigate end-of-life issues; and much more. A templated, user-friendly format makes it easy to find and apply the answers you need. See how to best manage geriatric cancer patients with help from leading specialists in both geriatrics and oncology Make informed decisions as to when to refer patients to specialists. Provide the supportive care your patients and their families need on issues such as such as mental health, pain, fatigue, nausea, insomnia. Be prepared to help cancer survivors navigate their after-treatment care including adjuvant therapy, side effects, second cancers, quality of life, and other concerns. Offer accurate guidance on ethical issues like competency, end of life, hospice, the role of the caregiver, and more.

For the first time, a single reference identifies medical technology assessment programs. A valuable guide to the field, this directory contains more than 60 profiles of programs that conduct and report on medical technology assessments. Each profile includes a listing of report citations for that program, and all the reports are indexed under major subject headings. Also included is a cross-listing of technology assessment report citations arranged by type of technology headings, brief descriptions of approximately 70 information sources of potential interest to technology assessors, and addresses and descriptions of 70 organizations with memberships, activities, publications, and other functions relevant to the medical technology assessment community.

Endocrine Biomarkers: Clinical Aspects and Laboratory Determination covers all the pre-analytical variables that can affect test results, both in the clinic and laboratory. Biomarkers of endocrine and bone diseases are discussed from both clinical and laboratory perspectives, and the authors elaborate on the teamwork-based app+roach between the clinician and the laboratory professional in the diagnosis and management of endocrine and bone disorders. Discussions include test utilization, laboratory measurement methods, harmonization and standardization, interpretation of results, and reference intervals. Each chapter ends with a discussion of one or two relevant cases with shared opinions from both a clinician and a clinical chemist. Each chapter also includes a summary box outlining key points and common pitfalls in the use of specific disease biomarkers and tests. - Focuses on the traditional, current, and emerging clinical chemistry tests for endocrine and bone diseases, along with their application in individual clinical management - Presents a brief discussion of each disorder and its respective interrelationships, along with laboratory methodologies that can be used to aid in evaluation of disorders - Reviews common approaches to the measurement of the relevant hormones, with a special focus on measures that require a structured clinical testing scenario - Reviews novel chemistry tests as potential means of future diagnostic tests - Provides an overview of the current methodology and controversies in the concept of target lipid levels, paying particular attention to the role of clinical chemistry in helping to implement population health targets

From the Surveill., Epidem., & End Results (SEER) Prog. based at the Nat. Cancer Inst. Intended as a coding manual beginning with cases diagnosed from Jan. 1, 2001 rather than a staging guide. Each anatomic site in the Topography Sect. of the Internat. Class. of Disease for Oncology -- 3rd Ed. (ICD-0-3) has a corresponding summary staging scheme. Certain specific histologic types also have specific staging schemes. In some cases, sites which previously had separate guides (such as the segments of the colon) have a single staging scheme (colon), whereas some sites which previously had a single guide (e.g., larynx) have separate schemes for each sub-site of the larynx.